Form 6K Immatics NV For: 21 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immatics NV (IMTX)
The Immatics NV share price today is 11.15 %REPORT_CURRENCY%, view NASDAQ IMTX stock exchange data. Track the latest Immatics NV share price with real-time updates on IMTX stock performance including market cap, day range, 52-week range and dividend yield. Access IMTX charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.97
11.30
52 wk Range
3.94
12.41
IMTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.9711.30
52 wk Range
3.9412.41
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
18.75
Upside
+68.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 6K Immatics NV For: 5 March
- Investing.com
- Immatics NV receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 6K Immatics NV For: 21 April
- Investing.com
- Form 6K Immatics NV For: 17 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Compare IMTX to Peers and Sector
Metrics to compare | IMTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −2.1x | −0.5x | |
PEG Ratio | 0.01 | −0.25 | 0.00 | |
Price/Book | 2.7x | 1.8x | 2.6x | |
Price / LTM Sales | 26.8x | 7.1x | 3.2x | |
Upside (Analyst Target) | 59.9% | 392.3% | 45.2% | |
Fair Value Upside | Unlock | 22.5% | 6.4% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 18.75
(+68.16% Upside)
Earnings
Latest Release
05-03-2026
EPS / Forecast
-0.28 / -0.41
Revenue / Forecast
19M / 9.59M
FAQ
What Is the Immatics NV (IMTX) Share Price Today?
The Immatics NV share price today is 11.15 EUR.
What is the current Immatics NV (IMTX) share price and day range?
As of 23-04-2026, the Immatics NV share price is 11.15 EUR, with a previous close of 11.26 EUR. The share price has ranged from 10.97 to 11.30 EUR today, while the 52-week range spans from 3.94 to 12.41 EUR.
What Is the Immatics NV Market Cap?
As of today, Immatics NV market cap is 1.49B.
What Is the Immatics NV (IMTX) Share Price Target?
The average 12-month share price target for Immatics NV is 18.75 EUR, with a high estimate of 25 EUR and a low estimate of 11 EUR. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +68.16% Upside potential.
What Is Immatics NV's Earnings Per Share (TTM)?
The Immatics NV EPS (TTM) is -1.61.
When Is the Next Immatics NV Earnings Date?
Immatics NV will release its next earnings report on 19-05-2026.
From a Technical Analysis Perspective, Is IMTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Immatics NV Trade On?
Immatics NV is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immatics NV?
The stock symbol for Immatics NV is "IMTX."
How Many Times Has Immatics NV Stock Split?
Immatics NV has split 0 times.
How Many Employees Does Immatics NV Have?
Immatics NV has 650 employees.
What Is the IMTX Premarket Price?
IMTX's last pre-market stock price is 11.17 EUR. The pre-market share volume is 20.00, and the stock has changed by -0.09 EUR, or -0.80%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.